NCT06963411View on ClinicalTrials.gov

Phase 1 Crossover Study Evaluating the Safety, Tolerability, and Pharmacokinetics of KP001 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

July 18, 2025

Study Completion Date

July 18, 2025

Conditions

Acute Allergic ReactionAnaphylaxis

Interventions

DRUG

KP001

Epinephrine Inhalation Aerosol (0.125 mg per inhalation)

DRUG

Placebo

Matched Placebo control (KP001 vehicle only)

Trial Locations (1)

G1P 0A2

Syneos HealthClinique Inc., Québec

Sponsors

Lead Sponsor

Kokua Pharma Inc.

All Listed Sponsors

lead

Kokua Pharma Inc.

OTHER

NCT06963411 - Phase 1 Crossover Study Evaluating the Safety, Tolerability, and Pharmacokinetics of KP001 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter